iShares Biotechnology ETF (IBB)

NASDAQ: IBB · Real-Time Price · USD
129.73
-2.01 (-1.53%)
At close: Jul 18, 2025, 4:00 PM
130.28
+0.55 (0.42%)
After-hours: Jul 18, 2025, 5:25 PM EDT
-1.53%
Assets$5.23B
Expense Ratio0.45%
PE Ratio18.58
Shares Out41.70M
Dividend (ttm)$0.38
Dividend Yield0.30%
Ex-Dividend DateMar 18, 2025
Payout Frequencyn/a
Payout Ratio5.53%
Volume1,113,965
Open132.15
Previous Close131.74
Day's Range129.44 - 132.96
52-Week Low107.43
52-Week High150.57
Beta0.73
Holdings260
Inception DateFeb 5, 2001

About IBB

Fund Home Page

The iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.

Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol IBB
ETF Provider BlackRock
Index Tracked NYSE Biotechnology

Top 10 Holdings

47.26% of assets
NameSymbolWeight
Vertex Pharmaceuticals IncorporatedVRTX7.97%
Amgen Inc.AMGN7.79%
Gilead Sciences, Inc.GILD7.49%
Regeneron Pharmaceuticals, Inc.REGN6.54%
Alnylam Pharmaceuticals, Inc.ALNY4.62%
IQVIA Holdings Inc.IQV3.12%
Mettler-Toledo International Inc.MTD2.81%
argenx SEARGX2.55%
Natera, Inc.NTRA2.20%
Biogen Inc.BIIB2.16%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Mar 18, 2025$0.12117Mar 21, 2025
Dec 17, 2024$0.06237Dec 20, 2024
Sep 25, 2024$0.20047Sep 30, 2024
Mar 21, 2024$0.12599Mar 27, 2024
Dec 20, 2023$0.12396Dec 27, 2023
Sep 26, 2023$0.15316Oct 2, 2023
Full Dividend History

Performance

IBB had a total return of -11.12% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.87%.

News

Trump's deadline looms for Big Pharma companies facing new tariffs

'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.

Other symbols: XLV
2 days ago - Fox Business

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.

Other symbols: XLV
5 days ago - WSJ

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

However, the President did not disclose when the tariffs would take effect.

Other symbols: CPERXBI
9 days ago - The Street

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar o...

Other symbols: XBI
12 days ago - Seeking Alpha

5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs

The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fuelin...

13 days ago - Seeking Alpha

Fast Money: WTI, IBB, UBER, CAT

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: UBERCAT
5 weeks ago - CNBC Television

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

7 weeks ago - Seeking Alpha

IBB: Now Is The Time To Be Contrarian

Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks...

7 weeks ago - Seeking Alpha

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

7 weeks ago - CNBC Television

Trump is right about drug prices. He's just going about it all wrong.

The stock market doesn't believe the president about prescription drugs.

Other symbols: XBIXLV
2 months ago - Market Watch

New vaccine chief rocks pharmaceutical stocks

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

2 months ago - CNBC Television

Trump Says Pharmaceutical Tariffs Coming in Near Future

President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...

3 months ago - Bloomberg Markets and Finance

Sell into strength in pharma, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.

Other symbols: XBI
3 months ago - CNBC Television

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...

3 months ago - CNBC

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Political pressure and persistently high interest rates have some wondering if the industry's model is broken.

Other symbols: XBI
3 months ago - WSJ

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

3 months ago - CNBC Television

Explainer: Prescription drugs become a target in Trump's trade war

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...

3 months ago - Reuters

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

3 months ago - CNBC

Why drug stocks are no longer a safe haven from the stock market's turmoil

Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.

3 months ago - Market Watch

Invest In A New Biotech Bull Market With XBI And IBB

Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides mor...

Other symbols: XBI
4 months ago - Seeking Alpha

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...

5 months ago - Seeking Alpha

How tariffs could impact pharma and early-stage healthcare investments

Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.

Other symbols: XLV
5 months ago - CNBC Television

Biotech walks a 'tightrope' amid unclear funding, regulations

Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se...

Other symbols: DCTHELVN
6 months ago - Yahoo Finance

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

6 months ago - Seeking Alpha

iShares Biotechnology ETF: Playing Defense

The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is retu...

7 months ago - Seeking Alpha